会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • 폴리갈라 카렌시움 추출물 및 이로부터 분리된 잔톤계 화합물을 함유하는 감기, 조류 인플루엔자, 돼지 인플루엔자 또는 신종플루의 예방 또는 치료용 조성물
    • 包含用于治疗或预防感冒,AVIAN INFLUENZA,SWINE INFLUENZA或NOVEL INFLUENZA分离的聚甘氨酸或其他化合物的组合物的组合物
    • KR101334143B1
    • 2013-11-28
    • KR1020120062490
    • 2012-06-12
    • 조선대학교산학협력단주식회사 중앙백신연구소
    • 오원근다오트롱투완누엔버치트최환원원호근윤인중
    • A61K31/352A61K31/35A61P31/16A61P31/12
    • The present invention relates to a composition containing a Polygala karensium extract and xanthone-based compounds isolated from the same for preventing or treating flu, avian influenza, swine influenza, or novel swine-origin influenza. The Polygala karensium extract and xanthone-based compounds isolated from the same effectively and non-selectively suppress neuraminidase of flu virus, avian influenza virus, swine influenza virus, novel swine-origin influenza, and Tamiflu resistant novel swine-origin influenza virus, thereby being used as a therapeutic agent for treating flu, avian influenza, swine influenza, and swine-origin influenza and being applied in cosmetic products, health foods, animal feeds, and an animal medicinal industry. [Reference numerals] (AA) Swine influenza virus (H1N1);(BB,HH,NN,TT) Compound 1;(CC,II,OO,UU) Compound 2;(DD,JJ,PP,VV) Compound 3;(EE,KK,QQ,WW) Compound 4;(FF,LL,RR,XX) Compound 5;(GG) Avian influenza virus (H9N2);(MM) Novel swine-origin influenza virus (novel H1N1);(SS) Novel swine-origin influenza virus resistant to Tamiflu (H1N1[H274Y])
    • 本发明涉及含有从其分离的Polygala karensium提取物和基于呫吨酮的化合物预防或治疗流感,禽流感,猪流感或新型猪源性流感的组合物。 从同样有效和非选择性地抑制流感病毒,禽流感病毒,猪流感病毒,新型猪源性流感病毒和Tamiflu抗性新型猪源性流感病毒的神经氨酸酶分离的Polygala karensium提取物和基于呫吨酮的化合物,从而被 用作治疗流感,禽流感,猪流感和猪源性流感的治疗剂,并用于化妆品,保健食品,动物饲料和动物医药行业。 化合物1;(CC,II,OO,UU)化合物2;(DD,JJ,PP,VV)化合物3;(AA)猪流感病毒(H1N1);(BB,HH,NN,TT) (EE,KK,QQ,WW)化合物4;(FF,LL,RR,XX)化合物5;(GG)禽流感病毒(H9N2);(MM)新型猪源性流感病毒(新型H1N1) )抗Tamiflu(H1N1 [H274Y])新型猪源性流感病毒
    • 7. 发明公开
    • 돼지 위축성 비염용 유전자재조합 백신
    • 重组疫苗用于磷酸盐性胃炎疾病
    • KR1020080039078A
    • 2008-05-07
    • KR1020060106785
    • 2006-10-31
    • 주식회사 중앙백신연구소
    • 유성식윤인중최환원원호근
    • A61K39/102A61P11/00
    • A61K39/102Y10S424/825
    • A recombinant vaccine for porcine atropic rhinitis is provided to be a pure toxoid, which is mass-produced within a short time using gene recombination technique, reduce the frequency of vaccination and be very effective for preventing secondary respiratory diseases as well as the porcine atropic rhinitis. A vaccine for porcine respiratory diseases such as porcine atropic rhinitis comprises: a recombinant Pasteurella multocida toxin(rPMT) which is prepared by the steps of: (a) providing an expression vector where a DNA sequence of SEQ ID : NO. 3 encoding a Pasteurella multocida toxin(PMT) is operably linked; (b) introducing the expression vector into a host cell such as E. coli; and (c) isolating and purifying the rPMT expressed from the host cell; a Bordetella bronchiseptica fungus body; a Pasteurella multocida type A fungus body; and a pharmaceutically acceptable adjuvant.
    • 提供了一种用于猪慢性鼻炎的重组疫苗,是一种纯的类毒素,它使用基因重组技术在短时间内大规模生产,减少疫苗接种次数,对于预防继发性呼吸道疾病以及猪慢性鼻炎具有非常有效的作用 。 一种用于猪呼吸道疾病如猪呼吸道炎症的疫苗包括:重组多杀巴斯德氏菌毒素(rPMT),其通过以下步骤制备:(a)提供表达载体,其中SEQ ID NO: 3编码多杀巴斯德氏杆菌毒素(PMT)可操作地连接; (b)将表达载体导入宿主细胞如大肠杆菌; 和(c)分离和纯化由宿主细胞表达的rPMT; 支气管炎博德特氏菌体; A型真菌多杀巴斯德氏菌体; 和药学上可接受的佐剂。